Hepion Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Hepion Pharmaceuticals reports significant losses and going concern doubt, pivoting from drug development to diagnostic tests after winding down its lead clinical trial and delisting from Nasdaq.
OQB
10-K: Hepion Pharmaceuticals Faces Going Concern Doubt Amidst Strategic Shift and Merger Termination
Hepion Pharmaceuticals reports its 2024 financial results, highlighting a strategic restructuring, termination of a merger agreement, and substantial doubt about its ability to continue as a going concern.
OQB
10-K/A: Hepion Pharmaceuticals Files Amended 10-K to Correct Executive Compensation and Ownership Data
Hepion Pharmaceuticals has filed an amendment to its Form 10-K/A to correct errors in executive compensation and security ownership information.
OQB
Hepion Pharmaceuticals has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.
OQB
Hepion Pharmaceuticals' 2023 annual report details a strategic restructuring plan to preserve capital, ongoing clinical trials for rencofilstat, and financial losses.